Oncopeptides AB (SE:ONCO)
:ONCO
Want to see SE:ONCO full AI Analyst Report?
ONCO Stock Chart & Stats
kr4.88
>-kr0.01(-0.39%)
At close: 4:00 PM EST
kr4.88
>-kr0.01(-0.39%)
Day’s Range― - ―
52-Week Rangekr1.26 - kr6.19
Previous CloseN/A
Volume80.98K
Average Volume (3M)2.28M
Market Cap
kr757.09M
Enterprise Valuekr369.17M
Total Cash (Recent Filing)kr70.15M
Total Debt (Recent Filing)kr124.23M
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding387,851,200
10 Day Avg. Volume1,913,694
30 Day Avg. Volume2,284,999
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-18.53
Price to Sales (P/S)15.35
P/FCF Ratio-4.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.44
Revenue Forecast (FY)kr150.00M
Bulls Say, Bears Say
Bulls Say
Very High Gross Margins (~97%)An exceptionally high product-level gross margin (~97%) indicates Pepaxti has a highly scalable cost structure and strong unit economics. If commercial volumes scale, these margins enable operating leverage and durable contribution to profitability once fixed commercial costs are covered.
Strong Revenue Rebound And Commercial TractionA 125% YoY revenue increase shows meaningful market adoption in core European markets. Sustained revenue growth evidences product-market fit and beginning commercialization scale, providing a durable foundation to leverage high gross margins and improve operating leverage over the next 2–6 months.
Market Exclusivity And Initial Patient BaseLong European market exclusivity through 2037 and an established treated patient base (>600) create a multi-year revenue runway. Early country-level success (Italy) demonstrates repeatable launch playbooks and provides structural protection versus competitors while partnerships expand reach.
Bears Say
Negative Equity And Weakened CapitalizationNegative shareholders' equity signals erosion of the capital base and materially reduces financial flexibility. Over the medium term this heightens refinancing and covenant risk, constrains strategic optionality, and increases likelihood of dilutive or costly funding if commercial ramps underperform.
Persistent Heavy Cash BurnSustained large negative operating and free cash flows indicate internal cash generation does not yet cover operating and R&D spend. Persistent burn creates recurring funding needs, raises dilution risk, and means long-term plans depend on successful commercialization or external capital.
Funding Dependence And Delayed Cash‑flow PositivityThe planned SEK 200m rights issue and pushed-out cash‑flow positivity underline dependency on external capital and execution. Delays increase exposure to market, commercial setbacks (Spain/Germany) and partnership timing, making long-term profitability contingent on successful, timely funding and adoption.
Oncopeptides AB News
ONCO FAQ
What was Oncopeptides AB’s price range in the past 12 months?
Oncopeptides AB lowest stock price was kr1.25 and its highest was kr6.19 in the past 12 months.
What is Oncopeptides AB’s market cap?
Oncopeptides AB’s market cap is kr757.09M.
When is Oncopeptides AB’s upcoming earnings report date?
Oncopeptides AB’s upcoming earnings report date is Aug 27, 2026 which is in 97 days.
How were Oncopeptides AB’s earnings last quarter?
Oncopeptides AB released its earnings results on May 13, 2026. The company reported -kr0.12 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.12.
Is Oncopeptides AB overvalued?
According to Wall Street analysts Oncopeptides AB’s price is currently Overvalued.
Does Oncopeptides AB pay dividends?
Oncopeptides AB does not currently pay dividends.
What is Oncopeptides AB’s EPS estimate?
Oncopeptides AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncopeptides AB have?
Oncopeptides AB has 387,851,200 shares outstanding.
What happened to Oncopeptides AB’s price movement after its last earnings report?
Oncopeptides AB reported an EPS of -kr0.12 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 38.715%.
Which hedge fund is a major shareholder of Oncopeptides AB?
Currently, no hedge funds are holding shares in SE:ONCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncopeptides AB
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Xspray Pharma AB
―
Active Biotech AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---